Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols

BackgroundEstablished colorectal cancer cell lines subjected to different 5-fluorouracil (5-FU) treatment protocols are often used as in vitro model systems for investigations of downstream cellular responses to 5-FU and to generate 5-FU-resistant derivatives for the investigation of biological mechanisms involved in drug resistance. We subjected HCT116 colon cancer cells to two different 5-FU treatment protocols in an attempt to generate resistant derivatives: one that simulated the clinical bolus regimens using clinically-achievable 5-FU levels, the other that utilized serial passage in the presence of increasing 5-FU concentrations (continuous exposure). HCT116 Bolus3, ContinB, and ContinD, corresponding to independently-derived cell lines generated either by bolus exposure or continuous exposure, respectively, were characterized for growth- and apoptosis-associated phenotypes, and gene expression using 8.5 K oligonucleotide microarrays. Comparative gene expression analyses were done in order to determine if transcriptional profiles for the respective treatment derivatives were similar or substantially different, and to identify the signaling and regulatory pathways involved in mediating the downstream response to 5-FU exposure and possibly involved in development of resistance.ResultsHCT116 ContinB and ContinD cells were respectively 27-fold and >100-fold more resistant to 5-FU and had reduced apoptotic fractions in response to transient 5-FU challenge compared to the parental cell line, whereas HCT116 Bolus3 cells were not resistant to 5-FU after 3 cycles of bolus 5-FU treatment and had the same apoptotic response to transient 5-FU challenge as the parental cell line. However, gene expression levels and expression level changes for all detected genes in Bolus3 cells were similar to those seen in both the ContinB (strongest correlation) and ContinD derivatives, as demonstrated by correlation and cluster analyses. Regulatory pathways having to do with 5-FU metabolism, apoptosis, and DNA repair were among those that were affected by 5-FU treatment.ConclusionAll HCT116 derivative cell lines demonstrated similar transcriptional profiles, despite the facts that they were generated by two different 5-FU exposure protocols and that the bolus exposure derivative had not become resistant to 5-FU. Selection pressures on HCT116 cells as a result of 5-FU challenge are thus similar for both treatment protocols.

[1]  Z. Darżynkiewicz,et al.  Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. , 1993, Cancer research.

[2]  D. Hedley,et al.  The death-promoting activity of p53 can be inhibited by distinct signaling pathways. , 2002, Blood.

[3]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[4]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[5]  O. Legrand,et al.  JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. , 2001, Blood.

[6]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[7]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[8]  David G. Kirsch,et al.  Caspase-3-dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c * , 1999, The Journal of Biological Chemistry.

[9]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[10]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[11]  A. Mathur,et al.  Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. , 2000, Cardiovascular research.

[12]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[13]  A. Gao,et al.  Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.

[14]  R. Handschumacher,et al.  Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. , 1995, Biochemical pharmacology.

[15]  B. Barton,et al.  IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells , 2001, BMC Cancer.

[16]  B. Dörken,et al.  Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop , 2003, Oncogene.

[17]  J. Turkson,et al.  Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity* , 2000, The Journal of Biological Chemistry.

[18]  E. Klein,et al.  Hormonal therapy for prostate cancer: primum non nocere. , 2002, Urology.

[19]  C. Allegra,et al.  Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. , 1995, Biochemical pharmacology.

[20]  A. Goel,et al.  Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines , 2003, International journal of cancer.

[21]  R. Jove,et al.  Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.

[22]  M. Gleave,et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[24]  M. Hawn,et al.  Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. , 1995, Cancer research.

[25]  F. Berger,et al.  Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. , 1993, Molecular pharmacology.

[26]  R. Oyasu,et al.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.

[27]  I. Pastan,et al.  Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. , 1994, The Journal of urology.

[28]  G. Peters,et al.  Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.

[29]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Berger,et al.  A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. , 1988, Molecular pharmacology.

[31]  M. David,et al.  Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. , 2000, The Journal of biological chemistry.

[32]  H. Fuse,et al.  Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. , 2001, Biochemical and biophysical research communications.

[33]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[34]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[35]  Takeshi Tokuhisa,et al.  Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation , 2002, The Journal of experimental medicine.

[36]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Karras,et al.  STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. , 2000, Cellular immunology.

[38]  P. Lamb,et al.  Pharmaceutical intervention in the JAK/STAT signaling pathway , 2000, Oncogene.

[39]  Trond Stokke,et al.  Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. , 2004, International journal of oncology.

[40]  I Lebedeva,et al.  Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. , 2000, Cancer research.

[41]  K Imada,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[42]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[43]  M. Marcelli,et al.  Overexpression of BCL-XL Underlies the Molecular Basis for Resistance to Staurosporine-induced Apoptosis in PC-3 Cells , 2001 .

[44]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[45]  A. Elefanty,et al.  Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. , 2001, Blood.

[46]  J. Carethers,et al.  Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. , 2000, In vivo.

[47]  G. Kruh Introduction to resistance to anticancer agents , 2003, Oncogene.

[48]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[49]  L. Milas,et al.  Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. , 2002, Cancer letters.

[50]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[51]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[52]  H Kishi,et al.  Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. , 2000, Biochemical and biophysical research communications.

[53]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[54]  T. Savarese,et al.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.

[55]  B. Bonavida,et al.  Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[58]  S. Beaucage,et al.  Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. , 2001, Molecular pharmacology.

[59]  M. Gleave,et al.  Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. , 2001, Urology.

[60]  J. Lammers,et al.  STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.

[61]  P. Johnston,et al.  Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.

[62]  M. Masuda,et al.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.

[63]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[64]  J. Ihle,et al.  STATs and MAPKs: obligate or opportunistic partners in signaling. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[65]  D. Tweardy,et al.  Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.

[66]  R. Lothe,et al.  Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. , 1998, Molecular Pathology.

[67]  J. Grandis,et al.  STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[68]  S. Kaye,et al.  Drug resistance reversal--are we getting closer? , 2003, European journal of cancer.

[69]  A. Belldegrun,et al.  Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. , 1995, Cancer research.

[70]  J. Nelson,et al.  Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice , 2002, The Prostate.